BRAF and non-small cell lung carcinoma: A case with the BRAF G596V mutation responded partially to vemurafenib [101], and while early studies on BRAF inhibitors in NSCLC were promising [102], only V600E mutations, not non-V600 mutations, showed clinical responses [103].